



OUTSOURCING

## **The CRO Market Outlook To 2014**

Emerging markets, leading players and future trends

By GC Green

## **GC Green**

GC Green is a healthcare analyst at Business Insights. He has previously conducted academic research into obesity, authoring various peer-reviewed reports and journal articles, also presenting at international conferences. He has a bachelor's degree in Psychology from the University of Bristol and an MSc in Occupational Psychology from the University of Nottingham.

Copyright © 2009 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

# Table of Contents

## The CRO Market Outlook to 2014

<b>Executive Summary</b>	<b>12</b>	
The global contract research organization market	12	
CRO market analysis	13	
Established regions in the global CRO market	14	
Emerging regions in the global CRO market	14	
Leading players in the global CRO market	15	
The future of contract research	16	
<b>Chapter 1</b>	<b>The global contract research organization market</b>	<b>20</b>
Summary		20
<b>Introduction</b>		21
The CRO contribution to drug development		21
Market overview		23
Key market drivers		23
Key market restraints		24
Conclusions and key findings		25
<b>Overview of the global CRO market</b>		26
Total revenue forecasts		26
Global R&D expenditure and CRO market size		27
Global clinical development outsourcing		28
The contribution of CRO to drug development		29
<b>Current market drivers</b>		31
Growth of R&D expenditure from biotech and pharma		31
Cost pressures encourage R&D outsourcing		33
Long term growth and R&D expenditure of biotechnology companies		36
Growing regulatory burden and safety concerns		37
US		37
EU		38
Patient recruitment		39
Increasing number of products in development		39
The development of biomarkers		40

<b>Current market restraints</b>	<b>41</b>
Near term reductions in biotech R&D spending	41
Growing competition and customer consolidation	42
New financial realities alter biopharmaceutical outsourcing landscape	43
Shortage of clinical research personnel	43
Electronic data capture: a threat to CRO revenue	44
<b>Key market trends</b>	<b>46</b>
Globalization	46
EDC evolution	46
Strategic alliances	47

## **Chapter 2                      CRO market analysis                      52**

<b>Summary</b>	<b>52</b>
<b>Introduction</b>	<b>53</b>
<b>Market conditions</b>	<b>53</b>
<b>Competitive analysis</b>	<b>54</b>
Market share analysis	54
Competitive dynamics	55
Academic medical centers	56
Site management organizations	57
Laboratory analytical services	58
Non-CRO niche service providers	59
Conclusion	59
<b>CRO service models</b>	<b>59</b>
Introduction	59
The full service model	60
SWOT analysis	63
The niche model	64
SWOT analysis	65
<b>Industry strategies</b>	<b>66</b>
Consolidation: Mergers & acquisitions in the CRO industry	66
Expanding the continuum of services: vertical integration	67
Forward integration	67
Backward integration	68
<b>Industry challenges</b>	<b>69</b>
Consolidation within the CRO industry: a threat to close customer relationships	69
Strategic outsourcing: demonstrating clear value to clients	70
Co-development: sharing the risk	71





Partnering collaborations and recent deals	138
<b>MDS Inc</b>	<b>139</b>
Company profile	139
Business description	139
Partnering collaborations and recent deals	140
<b>Kendle International</b>	<b>142</b>
Company profile	142
Business description	142
Partnering collaborations and recent deals	143
<b>PRA International</b>	<b>144</b>
Company profile	144
Business description	144
Partnering collaborations and recent deals	144
<b>PharmaNet Development Group</b>	<b>145</b>
Company profile	145
Business description	145
Partnering collaborations and recent deals	146

## **Chapter 6                      The future of contract research                      148**

Summary	148
Introduction	149
The shift towards a strategic model	149
Emerging markets	152
Phases I and IV growth activity	154
Electronic data capture	155
Biomarkers	157
Selected acquisitions/partnerships	159
Conclusion	160
Key findings and conclusions	161

## **Chapter 7                      Appendix                      164**

Selected bibliography	164
Index	166

# List of Figures

Figure 1.1:	Estimated CRO market (\$bn), 2003-2015e	26
Figure 1.2:	Global development expenditure and CRO market forecast (\$bn), 2008-2014e	27
Figure 1.3:	Global outsourcing market by phase, 2006	29
Figure 1.4:	CRO usage and number of days by which projects overrun	30
Figure 1.5:	Global pharmaceutical R&D expenditure (\$bn), 2000-2014e	32
Figure 1.6:	Number of FDA approvals 1990-2008	33
Figure 1.7:	Comparison of drug development cost estimates	34
Figure 1.8:	Global biotech R&D expenditure (\$bn), 2004-2012e	37
Figure 1.9:	Number of products in development by phase 1998-2009	40
Figure 1.10:	CRO/Sponsor relationship models	48
Figure 2.11:	Market share of major players, 2008	55
Figure 2.12:	Typical full service CRO model	61
Figure 3.13:	R&D expenditures of PhRMA members and non-member companies (\$bn), 1980-2009	76
Figure 3.14:	Overall indexed clinical trial costs by region, 2006-2008	79
Figure 3.15:	The European CRO market – revenue forecast (\$bn), 2008-2012e	81
Figure 3.16:	Pharmaceutical R&D expenditure in Europe (\$bn), 1990-2008	82
Figure 4.17:	Geographic distribution of clinical trials, 2005 to 2009f	90
Figure 4.18:	Clinical trial costs of European countries compared to the UK	92
Figure 4.19:	Comparison of trial registration periods in CEE countries (days)	93
Figure 4.20:	CRO market in China (\$m), 2007-2012e	98
Figure 4.21:	China’s capabilities across the value chain	101
Figure 4.22:	India’s capabilities across the value chain	108
Figure 4.23:	Number of clinical trials in Latin America, 2000-2008	111
Figure 4.24:	Clinical trials in South Korea, 2005-2009e	117
Figure 5.25:	Revenue growth of top public CROs in 2007-2008	123
Figure 5.26:	Capabilities of leading CROs, 2009	126
Figure 6.27:	Regional presence of major CROs	152
Figure 6.28:	Attractiveness of selected countries for clinical trials	153
Figure 6.29:	Global numbers of phase IV trials 2006-2009e	155
Figure 6.30:	Electronic data capture market size (\$m), 2006E-2012e	157
Figure 6.31:	Clinical trials using predictive biomarkers, 2005-2009	158

# List of Tables

Table 1.1:	Functions commonly performed by CROs	22
Table 2.2:	The global R&D outsourcing market: five major segments	56
Table 2.3:	SWOT analysis: the full service model	63
Table 2.4:	SWOT analysis: the niche model	65
Table 2.5:	Key deals in the CRO sector	67
Table 4.6:	Major CROs operating in Eastern Europe, 2009	96
Table 4.7:	Domestic Chinese CROs	103
Table 4.8:	Major domestic CROs operating in Latin America, 2009	116
Table 4.9:	Selected domestic CROs in South Korea and Turkey	120
Table 5.10:	Revenues (\$m) and growth of major CROs, 2007-2008	124

